KaydedilenlerDerginizi ekleyin

Dergiler / European Journal of Breast Health / 2022 / Cilt: 18 - Sayı: 3

An Overview of the Impact of Body Mass Index on Pathological Complete Response Following Neoadjuvant Chemotherapy in Operable Breast Cancer in a Tertiary Care Centre in South India

Poonam PATIL
Nitin YASHAS
BC ASHOK
Susmita RAKSHIT
Amit RAUTHAN
SP SOMASHEKHAR
Richa JAISWAL
Rohit KUMAR
HK KARTHIK
Archa PRASAD
Herra ISLAM
KR ASHWIN
Sayfa
271–278
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

All patients were initially divided into three groups depending on their pre-chemotherapy BMI.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The incidence of female breast cancer in the world is 11.7% with a mortality rate of 6.9%.
📊
Temel Bulgular & Veri:According to Globocon 2020, breast cancer is the most commonly diagnosed cancer (24.5%) and the leading cause of cancer-related death amongst women worldwide.
💡
Sonuç & Katkı:All patients were initially divided into three groups depending on their pre-chemotherapy BMI.
🔬Tür:Araştırma Makalesi
📍Kapsam:2020 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: The incidence of female breast cancer in the world is 11.7% with a mortality rate of 6.9%. According to Globocon 2020, breast cancer is the most commonly diagnosed cancer (24.5%) and the leading cause of cancer-related death amongst women worldwide. The purpose of this study was to analyze the impact of Body Mass Index (BMI) on pathological complete response (pCR) rates for operable breast cancer after neoadjuvant chemotherapy (NACT). The primary endpoint was to assess histopathological features of the surgical specimen in response to NACT and to investigate the relationship with pre-chemotherapy BMI taking into account the various molecular subtypes of breast cancer. Materials and Methods: Patients with biopsy-proven breast carcinoma who underwent surgery after NACT between January 2017 and May 2021 were included. All patients were initially divided into three groups depending on their pre-chemotherapy BMI. With BMI

🔖

Bu Makaleye Atıf Yap

PATIL, P., YASHAS, N., ASHOK, B., RAKSHIT, S., RAUTHAN, A., SOMASHEKHAR, S., JAISWAL, R., KUMAR, R., KARTHIK, H., PRASAD, A., ISLAM, H., ASHWIN, K. (2022). An Overview of the Impact of Body Mass Index on Pathological Complete Response Following Neoadjuvant Chemotherapy in Operable Breast Cancer in a Tertiary Care Centre in South India. European Journal of Breast Health, Cilt: 18 - Sayı: 3, 271–278. https://ajindex.com/articles/510664

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021
  2. (PMID: 33538338). [Crossref] 2. Pischon T, Nimptsch K. Obesity and risk of cancer: an introductory overview. Recent Results Cancer Res 2016
  3. (PMID: 27909899). [Crossref] 3. Haslam DW, James WP. Obesity. Lancet 2005
  4. (PMID: 16198769). [Crossref] 4. Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev 2014
  5. (PMID: 24375928). [Crossref] 5. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi GN, et al. Prognostic value of body mass index in locally advanced breast cancer. Clin Cancer Res 2008
  6. (PMID: 18347172). [Crossref] 6. Kim SW, Chun M, Jung YS, Oh YT, Noh OK, Cho O. Impact of body mass index on local recurrence according to intrinsic subtype approximation in korean women with early stage invasive breast cancer receiving contemporary treatments. J Cancer 2021
  7. (PMID: 34149928). [Crossref] 7. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010
  8. (PMID: 20571870). [Crossref] 8. von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013
  9. (PMID: 24002511). [Crossref] 9. Weir CB, Jan A. BMI Classification Percentile And Cut Off Points. 2021 Jun 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing
  10. (PMID: 31082114). [Crossref] 10. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011
  11. 1736–1747. (PMID: 21709140) [Crossref] 11. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997
  12. (PMID: 9215816). [Crossref] 12